Hikma Narrows 2026 Profit Forecast to $740-$760M

12 sourcesUpdated Nov 5, 20261 min read

0

Hikma Narrows 2026 Profit Forecast to $740-$760M — Photo: Elements Interactive / Wikimedia Commons (Pexels)

Sponsored

Hikma Pharmaceuticals maintained its 2026 revenue-growth guidance of 2% to 4% and narrowed its expected operating-profit range to $740 million to $760 million, from $720 million to $770 million. The company raised its branded-business revenue-growth outlook to about 10%, from 6% to 8%, and expects the division’s core operating margin to approach 27%, citing strong demand in the Middle East and North Africa, new launches and a favorable product mix. That strength offsets a weaker outlook for Injectables, whose revenue is now expected to be broadly flat amid pricing pressure, lower contract-manufacturing activity in Europe and Canada, and supply disruptions; its margin forecast remains 27% to 28%. Hikma said its U.S. generics business is expected to remain broadly flat, while it continues investing in product launches, commercial operations and research and development.

Sponsored

In this story:

2026 corporate earnings forecasts and guidance updatesstory 4 of 4 · since Nov 5, 2026

Nov 5, 2026Nov 5, 2026

Nov 5, 2026Hikma Pharmaceuticals narrowed its 2026 operating profit outlook to $740 million–$760 million while keeping group revenue growth guidance at 2%–4%.
Nov 5, 2026Siemens Healthineers’ 2027 forecast calls for 4%–5% comparable revenue growth and adjusted earnings per share of €2.20–€2.40.
Nov 5, 2026Sony’s second-quarter operating profit rose 45%, driven by stronger games and film results, and raised its full-year profit forecast.